FILING ANALYSIS · THURSDAY, OCTOBER 29
ALNYLAM PHARMACEUTICALS, INC. ALNY — 8-K: Results of Operations and Financial Condition
positive
Alnylam reported strong Q3 2026 financial results with 52% growth in global net product revenues, driven primarily by Total TTR revenues of $1,150 million, and announced an expanded enrollment target for the TRITON-CM Phase 3 study of nucresiran, positioning it for success and strengthening the company's long-term position in TTR.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →